Immunoshield Therapeutics

Immunoshield Therapeutics is a pre-clinical stage biotech founded in 2020, based in San Diego, CA, USA. The company is developing a platform technology designed to protect transplanted cells from host immune attack, thereby enabling universal, off-the-shelf allogeneic cell therapies without the need for concomitant immunosuppression. This approach aims to solve a critical bottleneck in the field, potentially expanding the addressable patient population for cell therapies fivefold. The company is seeking pre-seed investment, is backed by a $1.8M NIH SBIR award, and is progressing towards large animal studies.

Proprietary technology platform designed to shield therapeutic cells from host immune rejection, enabling universal, off-the-shelf allogeneic cell therapies without the need for immunosuppression.

Immunoshield operates in a highly competitive space focused on enabling allogeneic cell therapies. Competitors include companies developing gene-edited hypoimmune cells (e.g., using CRISPR to delete HLA), cell encapsulation devices, and alternative immune-modulatory approaches. Large pharma and biotech firms are also investing heavily in internal solutions, making technological differentiation and speed critical.